David Eveleth

David Eveleth is currently CEO of Trefoil Therapeutics. Previously he was a consultant to several biotechnology companies and venture capital groups. Prior to this, David led the Ophthalmology Medicines Development Group at Pfizer, a franchise that realized peak sales of $1.8 billion. He has been involved in or led seven INDs, the approval of several new drugs, and the approval of two medical devices. David has experience in both biotech and pharmaceuticals with several different companies and across the neuroscience and ophthalmology therapeutic areas including roles in R&D, business development, and portfolio and decision analysis.

David received his PhD in Biology from the University of California, Irvine and was a Bank of America/Giannini Foundation fellow prior to joining the industry.